CAJ | 학술논문

自1991年建立首批伦理委员会，我国伦理事业在新药临床试验中作用越来越强。我国伦理委员会借助亚太地区民间的伦理委员会审查能力发展行动战略认证系统进一步发展。本文就我国目前伦理委员会审查能力发展行动战略（SIDCER）认证现状进行分析。
자1991년건립수비윤리위원회，아국윤리사업재신약림상시험중작용월래월강。아국윤리위원회차조아태지구민간적윤리위원회심사능력발전행동전략인증계통진일보발전。본문취아국목전윤리위원회심사능력발전행동전략（SIDCER）인증현상진행분석。
China′s ethic committee has played an increasingly significant role in clinical trials of new drugs since the establishment of the first batch of Institutional Review Boards in 1991.The Strategic Initiative for Developing Capacity in Ethical Review (SIDCER) of our country′s Insti-tutional Review Boards with those in Asia -Pacific area has made enor-mous strides.Status of our homeland′s ethics committee SIDCER recog-nition was analyzed in this paper.